Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study

Thomas Willigenburg1, Ellis Beld1, Jochem Hes, Jan J.W. Lagendijk, Hans C.J. de Boer, Marinus A. Moerland, Jochem R.N. van der Voort van Zyp

*Corresponding author at: University Medical Center Utrecht, Heidelberglaan 100, Postbus 85500, 3584 CX Utrecht, The Netherlands.
E-mail address: t.willigenburg-3@umcutrecht.nl (T. Willigenburg).

ARTICLE INFO

Keywords:
Prostate cancer
MR-Linac
Focal salvage high-dose-rate brachytherapy
SBRT
Single fraction
MRI-guided radiotherapy
Radiotherapy treatment planning

ABSTRACT

Background and Purpose: Magnetic resonance imaging (MRI)-guided focal salvage high-dose-rate brachytherapy (FS-HDR-BT) is one of the treatment options for radiorecurrent localized prostate cancer. However, due to the invasive nature of the treatment, not all patients are eligible. Magnetic resonance linear accelerator (MR-Linac) systems open up new treatment possibilities and could potentially replace FS-HDR-BT treatment. We conducted a planning study to investigate the feasibility of delivering a single 19 Gy dose to the recurrent lesion using a 1.5 Tesla MR-Linac system.

Materials and Methods: Thirty patients who underwent FS-HDR-BT were included. The clinical target volume (CTV) encompassed the visible lesion plus a 5 mm margin. Treatment plans were created for a 1.5 Tesla MR-Linac system using a 1 mm planning target volume (PTV) margin. A dose of 19 Gy was prescribed to ≥ 95% of the PTV. In case this target could not be reached, i.e. when organs-at-risk (OAR) constraints were violated, a dose of ≥ 17 Gy to ≥ 90% of the PTV was accepted. MR-Linac plans were compared to clinical FS-HDR-BT plans.

Results: Target dose coverage was achieved in 14/30 (47%) FS-HDR-BT plans and 17/30 (57%) MR-Linac plans, with comparable median D95% and D90%. In FS-HDR-BT plans, a larger volume reached ≥ 150% of the prescribed dose. Urethra D10%, rectum D1cm3, and rectum D2cm3 were lower in the FS-HDR-BT plans, while bladder dose was comparable for both modalities.

Conclusion: Single fraction treatment of recurrent prostate cancer lesions may be feasible using stereotactic body radiotherapy (SBRT) on a MR-Linac system.

1. Introduction

Up to 50% of the high-risk prostate cancer patients treated with primary dose-escalated radiation therapy develop a biochemical recurrence within 10 years of treatment [1,2]. In more than half of the patients with a recurrence detected on imaging, the recurrence is confined to the prostate and/or seminal vesicles [3]. A treatment option for local radiorecurrent prostate cancer is magnetic resonance imaging (MRI)-guided focal salvage high-dose-rate brachytherapy (FS-HDR-BT) [4,5]. With FS-HDR-BT, patients are treated in a single treatment session with a dose of 19 Gy to the clinical target volume (CTV). The radiation is delivered locally through catheters inserted via the perineum into the prostate using an Ir-192 source [4]. However, due to the invasiveness of the treatment and the need for spinal anesthesia, not all patients are eligible. Furthermore, a non-invasive treatment option will increase patient comfort.

The recent clinical introduction of magnetic resonance linear accelerator (MR-Linac) systems opens up a non-invasive treatment possibility that uses stereotactic body radiotherapy (SBRT) [6]. A MR-Linac integrates a MRI scanner with a linear accelerator [7]. This technology enables the visualization of the anatomy before and during treatment, allowing for daily adjustment of treatment plans [8,9]. This leads to improved targeting compared to current conventional SBRT. Consequently, radiation-oncologists can reduce safety margins and deliver a higher dose per fraction. These aspects could make the MR-Linac a viable non-invasive alternative to FS-HDR-BT for treatment of radiorecurrent prostate cancer in a single fraction.

We conducted a planning study to evaluate the feasibility of...
delivering a single 19 Gy dose to a locally radiorecurrent prostate cancer lesion using a 1.5 Tesla MR-Linac system. The MR-Linac plans were compared to the clinically delivered FS-HDR-BT plans.

2. Materials and methods

2.1. Patient characteristics

For this study, we included 30 patients that had previously been treated with FS-HDR-BT at the Department of Radiation Oncology of the UMC Utrecht between November 2014 and April 2019. Patients were included from two pre-existing FS-HDR-BT studies (Netherlands Trial Register numbers NTR6123 and NTR7014) approved by our institutional review board. Written informed consent was obtained for use of the data for this planning study. To make the results more generalizable, different tumor locations within the prostate were identified and patients were divided accordingly. Next, the 30 patients were selected randomly (using a random number table) from our patient database, taking into account the general tumor location, but without knowledge of the exact anatomy and FS-HDR-BT dose distribution. Baseline tumor characteristics of these 30 patients are displayed in Supplementary Table S1. The different tumor locations are visualized in Fig. 1.

2.2. Target definition

Pre-treatment delineations for the salvage FS-HDR-BT were performed using the in-house developed software Volumetool® by experienced prostate cancer radiation oncologists on diagnostic MRI and prostate specific membrane antigen (PSMA) positron emission tomography (PET) images. The gross tumor volume (GTV) consisted of the visible tumor and was expanded uniformly by 5 mm to create the clinical target volume (CTV), staying inside the prostate body and/or seminal vesicle anatomical boundaries. Prostatic urethra, rectum, and bladder were delineated. For FS-HDR-BT treatment planning, the planning target volume (PTV) was equal to the CTV (i.e. a CTV to PTV margin of 0 mm). For MR-Linac treatment planning, a CTV to PTV margin of 1 mm was adopted. This 1 mm margin has to account for additional uncertainties that are introduced with the use of a MR-Linac system compared to FS-HDR-BT. These uncertainties consist of intrafraction prostatic motion and geometrical (in)accuracy of the system. Prior investigations by our department showed that the geometrical accuracy of the Elekta MR-Linac system is on average 0.3 mm (range 0.2–0.4 mm) [6]. Concerning prostate motion, we have developed an accurate soft tissue prostate tracking algorithm with a mean error of 0.07 mm (SD 0.22 mm) [11,12]. Combined with new treatment planning systems developed at our department that facilitate online (intrafraction) replanning to account for anatomy shifts and changes, we assumed that a 1 mm PTV margin is achievable [9,13,14].

2.3. FS-HDR-BT treatment plan acquisition

The clinical FS-HDR-BT treatment plans, as delivered during treatment, were used in this study. During FS-HDR-BT, after insertion of the catheters, an intraoperative MRI scan was acquired. The diagnostic MRI scan was rigidly registered to the intraoperative MRI, followed by a transfer of the pre-treatment delineations to the intraoperative MRI. The delineations were adjusted according to the current anatomy. Furthermore, the positions of the brachytherapy catheters were reconstructed on the intraoperative MRI. The adjusted contours and reconstructed catheter positions were used for MRI-only dose calculation using Oncentra® Prostate (Version 4.2.2.4., Elekta). Between 6 and 15 catheters were used in these patients. A dose of at least 19 Gy was prescribed to 95% of the CTV (i.e. D95% ≥19 Gy). The dose constraints used for the organs-at-risk (OAR) are provided in Table 1. If the OAR constraints could not be met, a dose of at least 17 Gy to 90% of the CTV was accepted. The MRI-guided FS-HDR-BT treatment is extensively described elsewhere [4].

2.4. MR-Linac treatment plan acquisition

SBRT treatment planning requires patient body contours, which were missing for the FS-HDR-BT intraoperative MRI because of the

Fig. 1. Different tumor locations treated with FS-HDR-BT. A: peripheral tumor, not near any of the organs-at-risk. B: central tumor adjacent to the urethra. C: peripheral/lateral tumor between rectum and urethra. D: central tumor between rectum and urethra. E: tumor adjacent to bladder and urethra. F: peripheral tumor adjacent to rectum and not near urethra. G: tumor in seminal vesicles, adjacent to rectum and/or bladder. H: tumor in base of the prostate, adjacent to rectum and bladder, without seminal vesicle involvement.
and a MR-Linac plan. With the 50%, 100%, 150%, and 200% isodose-lines for a FS-HDR-BT (Supplementary Table S1). Fig. 2 shows an exemplary dose distribution and 2 cm³ of the OAR) were obtained. For the urethra, D10% (highest minimum segment width and area were 0.5 cm and 1.5 cm², respectively. The setup, with a 7 mm leaf width and a fixed collimator angle. The modulated radiotherapy (IMRT) plans were created using a 9-beam software includes the beam characteristics of the MR-Linac and the presence of a magnetic field and cryostat. The beam characteristics have extensively been described by Woodings et al. [15]. Intensity-modulated radiotherapy (IMRT) plans were created using a 9-beam setup, with a 7 mm leaf width and a fixed collimator angle. The minimum segment width and area were 0.5 cm and 1.5 cm², respectively. The minimum number of monitor units per segment was 5, with a maximum of 150 segments. A calculation grid spacing of 3 mm was used with a statistical uncertainty of 3% per control point and < 1% per voxel. A CTV to PTV margin of 1 mm was applied. The dose constraints were equal to those clinically applied in FS-HDR-BT. Hence, a dose of at least 19 Gy was prescribed to 95% of the PTV, allowing the CTV dose to reach above 19 Gy. OAR dose constraints are provided in Table 1. Furthermore, in case the OAR constraints could not be met, a dose of at least 17 Gy to 90% of the PTV was aimed for. Treatment planning was optimized for adequate target coverage with minimal dose to the OAR.

2.5. Evaluation of treatment plans

The simulated MR-Linac treatment plans were compared to the clinically delivered FS-HDR-BT plans. The CTV dose in the FS-HDR-BT plans was compared to the PTV dose in the MR-Linac plans. For the CTV/PTV target, the following dosimetric parameters were acquired: D90% and D95% (minimum dose to 90% and 95% of the target, respectively), V100%, V150%, and V200% (relative target volume receiving 100%, 150%, and 200% of the prescribed dose, respectively). For the bladder and rectum, D1cm³ and D2cm³ (highest dose to 1 cm³ and 2 cm³ of the OAR) were obtained. For the urethra, D10% (highest dose to 10% of the urethra) was collected. The median values (and range) of target volume coverage, high dose volumes and OAR doses were obtained. The paired data was compared using the non-parametric Wilcoxon signed-rank test. To correct for multiple testing, p-values < 0.01 were considered statistically significant. All analyses were performed using IBM SPSS Statistics 25 (Chicago, IL, USA).

3. Results

The delineated tumor volume (GTV) ranged from 0.7 cm³ to 17.8 cm³ and CTV volume ranged from 2.9 cm³ to 24.7 cm³ (Supplementary Table S1). Fig. 2 shows an exemplary dose distribution with the 50%, 100%, 150%, and 200% isodose-lines for a FS-HDR-BT and a MR-Linac plan.

Table 1 presents the dosimetric results for the FS-HDR-BT and MR-Linac plans. Out of the 30 FS-HDR-BT plans, 16 (53%) did not reach the prescribed dose of 19 Gy to ≥ 95% of the target, compared to 13 (43%) for the MR-Linac plans. Of the 16 plans that failed to meet the 19 Gy dose prescription for FS-HDR-BT, 5 succeeded with the MR-Linac. Contrarily, 2 out of the 13 that failed with the MR-Linac system, succeeded with FS-HDR-BT. Additionally, for both FS-HDR-BT and MR-Linac, two plans (7%) failed to meet the secondary dose prescription of at least 17 Gy to 90% of the target volume. All of these plans did, however, reach a dose of at least 17 Gy with the other treatment modality. The two plans that failed with FS-HDR-BT had a large CTV (33% and 60% of the prostate volume) surrounding the urethra. The two plans that failed with MR-Linac had a tumor located in the base and seminal vesicle, closely related to the bladder and rectum. In addition, no target volume received 200% (38.0 Gy) of the prescribed dose with MR-Linac treatment planning, whereas the median target volume receiving 38.0 Gy was 25% for FS-HDR-BT (p < 0.001). OAR dose constraints were met in all MR-Linac plans. In 5 (17%) FS-HDR-BT plans, OAR constraints were violated; in 3 (10%) cases the urethra D10% was > 17.7 Gy and in 2 cases (7%) the bladder D1cm³ was > 12 Gy. Median CTV/PTV D95% stratified by tumor location is presented in Table 3.
Table 2
Dosimetric parameters for FS-HDR-BT plans and MR-Linac plans for a single, 19 Gy dose prescription to the CTV and PTV respectively. *CTV for FS-HDR-BT and PTV for MR-Linac.

| Parameter                  | Reference dose | FS-HDR-BT | MR-Linac | Median (n = 30) | Range     | Median (n = 30) | Range     | p-value |
|----------------------------|----------------|-----------|----------|----------------|-----------|----------------|-----------|---------|
| Baseline                   |                |           |          |                |           |                |           |         |
| Target coverage            |                |           |          |                |           |                |           |         |
| D95% CTV/PTV*              | ≥ 19 Gy        | 18.8 Gy   | 14.0-21.7 Gy | 19.0 Gy        | 15.5-21.7 Gy | 0.053          |         |
| D90% CTV/PTV*              | ≥ 17 Gy        | 20.3 Gy   | 15.9-23.6 Gy | 20.2 Gy        | 16.7-22.6 Gy | 0.484          |         |
| High dose volumes          |                |           |          |                |           |                |           |         |
| V100% CTV/PTV*             | –              | 95%       | 73-99%   | 95%            | 69-100%   | 0.894          |         |
| V95% CTV/PTV*              | –              | 55%       | 25-77%   | 1%             | 0-38%     | < 0.001        |         |
| V80% CTV/PTV*              | –              | 25%       | 9-54%    | 0%             | 0-0%      | < 0.001        |         |
| OAR dose                   |                |           |          |                |           |                |           |         |
| Urethra D10%               | < 17.7 Gy      | 16.0 Gy   | 6.7-18.2 Gy | 17.5 Gy        | 8.2-17.7 Gy | < 0.001        |         |
| Rectum D1cm3               | < 12 Gy        | 10.2 Gy   | 4.1-12.0 Gy | 12.0 Gy        | 9.4-12.0 Gy | < 0.001        |         |
| Rectum D2cm3               | –              | 8.6 Gy    | 1.6-10.8 Gy | 10.7 Gy        | 8.4-11.3 Gy | < 0.001        |         |
| Bladder D1cm3              | < 12 Gy        | 8.5 Gy    | 1.8-12.1 Gy | 8.4 Gy         | 0.4-12.0 Gy | 0.102          |         |
| Bladder D2cm3              | –              | 7.0 Gy    | 1.6-10.8 Gy | 6.6 Gy         | 0.5-11.1 Gy | 0.090          |         |

Table 3
Median D95% coverage with ranges for the different tumor locations (both anatomical location and position with respect to organs-at-risk) for FS-HDR-BT and MR-Linac plans respectively. U = urethra. R = rectum. B = bladder.

| Location          | Near or between OAR? | N | Median (Gy) | Range (Gy) | Median (Gy) | Range (Gy) | p-value |
|-------------------|----------------------|---|-------------|------------|-------------|------------|---------|
| Peripheral        | No                   | 5 | 20.0        | 19.1-21.1  | 21.0        | 20.4-22.0  |         |
| Central           | U                    | 3 | 19.7        | 16.6-21.2  | 19.0        | 19.0-19.7  |         |
| Peripheral        | U and R              | 3 | 19.1        | 17.5-19.1  | 19.0        | 18.1-19.2  |         |
| Central           | U and R              | 4 | 18.4        | 17.7-18.7  | 18.5        | 17.4-19.3  |         |
| Peripheral        | U and B              | 3 | 15.2        | 14.0-21.7  | 17.7        | 17.0-20.7  |         |
| Seminal vesicles  | R                    | 4 | 19.7        | 18.6-21.1  | 19.1        | 18.8-20.1  |         |
| Base              | R and/or B           | 5 | 16.8        | 16.0-19.2  | 17.9        | 15.5-19.1  |         |

4. Discussion
We performed a comparative planning study to evaluate the feasibility of delivering a single 19 Gy dose to a local recurrent prostate cancer lesion using a 1.5 Tesla MR-Linac system. The simulated MR-Linac plans were compared to clinically delivered FS-HDR-BT plans. Both treatment planning techniques showed comparable target coverage (see Table 2), though with both techniques the target dose of 19 Gy was not reached for some cases. The SBRT technique combined with the additional 1 mm PTV margin resulted in a higher median dose to both the urethra and rectum for the MR-Linac plans. However, no OAR constraints were violated. Delivering a single 19 Gy dose to a recurrent prostate cancer lesion with acceptable target dose coverage, while respecting OAR constraints, thus seems feasible on a MR-Linac.

To our knowledge, no studies have investigated the feasibility of focal salvage SBRT to deliver a single fraction 19 Gy dose to an intraprostatic lesion in the recurrent setting with corresponding OAR constraints. Henderson et al. reported a planning study on single session treatment using SBRT and a 3 mm PTV margin [16]. They prescribed 15 Gy and 19 Gy to ≥ 95% and 65–75% of the PTV, respectively, with a boost of 21 Gy to ≥ 95% of the MRI-visible intraprostatic lesion plus a 3 mm margin. The median rectal D2cm3 was 14.4 Gy and median urethral V20.8 was 20.8%. However, the different treatment setting with different OAR constraints makes it hard to extrapolate these results to our study. Currently, Zilli et al. are investigating the delivery of a single 19 Gy dose to the whole prostate gland and two-thirds of the seminal vesicles with urethra sparing (down to 17 Gy) in a primary setting [17,18]. For bladder and rectum constraints, they use V20Gy < 1 cm3.

Again, because of the different setting and constraints, the results of this study are not directly comparable to our results.

OAR constraints were met for all MR-Linac plans. We found a higher median urethral and rectal dose with the MR-Linac plans compared to FS-HDR-BT. This can be explained by the more gradual dose fall-off with SBRT and the larger PTV. Besides a higher rectum D1cm3, the mean dose to the rectum is also likely to increase. However, limited data is available on toxicity in patients treated with focal salvage radiotherapy. In our FS-HDR-BT group, grade 2 and higher gastrointestinal (GI) toxicity was extremely low, with no grade 3 GI toxicity so far and only 4% new-onset grade 2 GI toxicity, as reported by Van Son et al. [19]. Although rectal dose is slightly higher with SBRT, it is still below the constraint and therefore low GI toxicity is expected. Bladder D1cm3 and D2cm3 were comparable for FS-HDR-BT and MR-Linac. This is probably caused by the more cranial position of the bladder with respect to the prostate and therefore this organ is easier to avoid with SBRT than the rectum. Again, the differences were quite small and probably clinically irrelevant. Nevertheless, prospective studies should assess this.

As expected, larger volumes receiving 150% or 200% of the prescribed dose were reached with FS-HDR-BT. A means to increase the volume receiving high dose levels using a MR-Linac might be to include an additional – higher – dose prescription to the GTV. A higher dose to the tumor potentially leads to longer biochemical progression-free survival (BPF). However, the exact relationship between these high-dose volumes and BPF in this patient group has to be established. Also, especially in this patient group with recurrent prostate cancer, radioresistance can play a role in oncologic outcomes of the treatment. Overall BPF ranges between 47% and 54% at 5-year follow-up and a recent update by Van Son et al. showed that 73% of the intraprostatic recurrences after FS-HDR-BT occurred in-field [19,20]. Accordingly, this may imply that treatment of these tumors might benefit from an increased dose. Dose escalation and/or fractionation could improve oncologic outcomes, but may go hand-in-hand with increased acute toxicity as suggested by Murgic et al. [21]. If future study results demonstrate improved oncologic outcomes by applying e.g. two or three fractions, the MR-Linac is a more attractive treatment modality due to the non-invasiveness and easier logistics.

Stratifying the target dose by tumor location showed areas with different OAR constraints and high-dose volume receiving high dose levels using a MR-Linac might be to include an additional – higher – dose prescription to the GTV. A higher dose to the tumor potentially leads to longer biochemical progression-free survival (BPF). However, the exact relationship between these high-dose volumes and BPF in this patient group has to be established. Also, especially in this patient group with recurrent prostate cancer, radioresistance can play a role in oncologic outcomes.

Survival (BPF). However, the exact relationship between these high-dose volumes and BPF in this patient group has to be established. Also, especially in this patient group with recurrent prostate cancer, radioresistance can play a role in oncologic outcomes.

Prostate cancer is often resistant to radiation therapy, leading to biochemical progression-free survival (BPF). However, the exact relationship between these high-dose volumes and BPF in this patient group has to be established. Also, especially in this patient group with recurrent prostate cancer, radioresistance can play a role in oncologic outcomes.

As expected, larger volumes receiving 150% or 200% of the prescribed dose were reached with FS-HDR-BT. A means to increase the volume receiving high dose levels using a MR-Linac might be to include an additional – higher – dose prescription to the GTV. A higher dose to the tumor potentially leads to longer biochemical progression-free survival (BPF). However, the exact relationship between these high-dose volumes and BPF in this patient group has to be established. Also, especially in this patient group with recurrent prostate cancer, radioresistance can play a role in oncologic outcomes.
Secondly, from a FS-HDR-BT perspective, we used clinically delivered plans, which reflect the real capabilities of the FS-HDR-BT treatment modality. Conversely, a limitation of this study is the fact that the MR-Linac plans are optional plans based on several assumptions. Firstly, we have used a 1 mm PTV margin. As discussed in the materials and methods section, this 1 mm margin has to account for additional uncertainty due to intrafraction prostatic motion and geometrical (in)accuracy that are introduced with the use of a MR-Linac system compared to FS-HDR-BT. Based on the mentioned prostate tracking algorithm and adaptive treatment planning systems that have been developed at our department, this 1 mm margin seems to be achievable [9,11,13,14]. Since interobserver contouring variability of the target is present in FS-HDR-BT as well, we do not expect this to lead to additional inaccuracy with MR-Linac treatments. Also, we believe that the full potential of MR-Linac systems lies in achieving these very small PTV margins that are not possible with conventional systems. Based on our prostate motion analyses, 3 to 4 mm margins are sufficient for current prostate cancer treatment without intra-fraction adaptation [12]. Enlarging the PTV margin in our study to i.e. 3 or 5 mm would thus not make full use of the MR-Linac system’s capabilities that distinguish it from conventional cone-beam CT linear accelerators. Still, this will remain hypothetical until it is technically possible to combine all the aforementioned developments into a clinically released system. Another limitation is the fact that we only had full field-of-view CT scans available for the MR-Linac treatment planning. The registration between the intraoperative MRI and the CT scan and the contour propagation could lead to differences in the exact dose distributions. However, these potential differences were assumed to be minor and have no impact on the planning comparison study. Thirdly, we used FS-HDR-BT OAR constraints for our evaluation. We assessed the highest dose to small volumes (1 cm³) for the rectum and bladder. Contrary to FS-HDR-BT, mean dose to OAR is generally higher with external beam radiotherapy due to the more gradual dose fall-off. However, delivery of a single 19 Gy dose to a focal recurrent tumor using a volumetric modulated arc therapy (VMAT)-like technique resembles SBRT. Several studies on ultra-hypofractionated and single session radiotherapy for prostate cancer use only high-dose to low-volume constraints, thereby showing low toxicity rates [18,22–24]. Accordingly, we argue that D1 cm³ is a sensible and important parameter allowing for comparison between the two treatment modalities. Fourthly, due to the small stratified sample sizes, we were unable to draw any definitive conclusions from the dosimetric analysis per tumor location. Lastly, by using the intra-operative delineations from the FS-HDR-BT treatment, we took into account the effect of volume changes (edema) that might have occurred during brachytherapy due to the insertion of catheters. While no volume changes will occur with MR-Linac treatment, we used the same delineations for MR-Linac treatment planning. Therefore, the volumes might not be completely representative for MR-Linac treatment. However, for a fair comparison of the dose distributions, no adaptations were made to the delineations to include identical target volumes for both treatment plans.

In conclusion, we showed that for the majority of the patients treated with FS-HDR-BT, we could create an acceptable and comparable MR-Linac plan. This demonstrated the feasibility of SBRT treatment planning for radio-recurrent prostate cancer using a single 19 Gy dose on a 1.5 Tesla MR-Linac system, while respecting FS-HDR-BT OAR constraints. Hence, MR-Linac systems may provide a non-invasive alternative to FS-HDR-BT. Research should be conducted on the necessity of the larger high-dose volumes achieved in FS-HDR-BT, which may favor oncological outcomes in the long-term. Before clinical application of salvage MR-Linac treatment, real-time intra-fraction adaptation and dose calculation should be technically enabled, and clinical feasibility has to be tested in early phase clinical trials.

5. Role of the funding source

This research has been partly funded by ZonMW (The Netherlands, IMDI project, grant 104006004), the LSH-TKI Foundation (The Netherlands, grant 104006004), and the Dutch Cancer Society (The Netherlands, grant 10392). The funding sources had no involvement in the design of the study, the collection, analysis, and interpretation of the data, nor in the writing and decision to submit the article for publication.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.phro.2020.07.006.

References

[1] Heemskerken WD, Al-Mamgani A, Slot A, Dieuwert MFH, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014;110:104–9. https://doi.org/10.1016/j.radonc.2013.09.026.

[2] Beckendorf V, Guerri S, Le Prist E, Cosset JM, Bourguix A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056–63. https://doi.org/10.1016/j.ijrobp.2010.03.049.

[3] Zamsteg ZS, Spratt DE, Romesser PB, Peti X, Zhang Z, Kollmeier M, et al. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose-Escalation Era for Prostate Patients Undergoing External Beam Radiotherapy. J Urol 2015;194:1624–30. https://doi.org/10.1016/j.juro.2015.06.100.

[4] Maenhout M, Peters M, van Vulpen M, Moerlang MA, Meijer RP, van den Bosch MAJ, et al. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radio recurrence Prostate Cancer. Technol Cancer Res Treat 2017;16:1194–201.

[5] Steele EM, Holmes JA. A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer. Urol Oncol Semin Orig Investig 2019;37:582–98. https://doi.org/10.1016/j.urolonc.2019.04.030.

[6] Raaymakers BW, Jurgenlikem-Schulz IM, Bol GH, Glitzner M, Kotte ANTJ, van Asselen B, et al. First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol 2017;62:4141–50. https://doi.org/10.1088/1361-6560/aa9517.

[7] Lagendijk JJW, Raaymakers BW, van Vulpen M. The Magnetic Resonance Imaging-Linear System. Semin Radiat Oncol 2014;24:207–9. https://doi.org/10.1016/j.sradonc.2014.02.001.

[8] de Muinck Keizer DM, Pathmanathan AU, Andreychenko A, Kerkmeijer LGW, van der Voort van Zyp JRN, Tree AC, et al. Fiducial marker based intra-fraction motion assessment on cine-MR for MR-linac treatment of prostate cancer. Phys Med Biol 2019;64:5073T2. https://doi.org/10.1088/1361-6560/ab9a66.

[9] Kontaxis C, Bol GH, Asselen B, Raaymakers BW. A new methodology for inter-and intrafraction plan adaptation for the MR-linac. Phys Med Biol 2015;60:7485–97. https://doi.org/10.1088/0031-9155/60/19/7485.

[10] Bol GH, Kotte ANTJ, van der Heide UA, Lagendijk JJW. Simultaneous modality ROI delineation in clinical practice. Comput Methods Programs Biomed 2009;96:133–40. https://doi.org/10.1016/j.cmpb.2009.04.008.

[11] de Muinck Keizer DM, Kerkmeijer LGW, Maspero M, Andreychenko A, van der Voort van Zyp JRN, van den Berg CAT, et al. Soft-tissue prostate intrafraction motion tracking in 3D cine-MR for MR-guided radiotherapy. Phys Med Biol 2019;64:235008. https://doi.org/10.1088/1361-6560/ab5539.

[12] de Muinck Keizer DM, Kerkmeijer LGW, Willigenburg T, van Lier ALHMW, de Hartogh MD, van der Voort van Zyp JRN, et al. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions. Radiat Oncol 2020. https://doi.org/10.1016/j.radonc.2020.06.044.

[13] Kontaxis C, Bol GH, Stensbøls K, Glitzner M, Prins FM, Kerkmeijer LGW, et al. Towards fast online intrafraction replanning for free-breathing stereotactic body radiation therapy with the MR-linac. Phys Med Biol 2017;62:7233–48. https://doi.org/10.1088/1361-6560/aa82ze.

[14] Kontaxis C, Bol GH, Lagendijk JJW, Raaymakers BW. DeepDose: towards a fast dose calculation engine for radiation therapy using deep learning. Phys Med Biol 2020;65:075013https://doi.org/10.1088/1361-6560/ab7630.

[15] Woodings SJ, Bluemink JJ, de Vries JHW, Niatsetski Y, van Veelen B, Schillings J, et al. Beam characterization of the 1.5 T MR-Linac: clinical proof of concept. Phys Med Biol 2014;60:64. https://doi.org/10.1088/0031-9155/60/24/7485.

[16] Henderson D, Tree A, van As N. Single Fraction External Beam Radiotherapy for...
Localised Prostate Cancer: a Planning Study. Clin Oncol 2017;29:e87. https://doi.org/10.1016/j.clon.2016.11.018.

[17] Zilli T, Koustouvelis N, Miralbell R, Scorsetti M, Franzese C, D’Agostino GR, et al. ONE SHOT - single shot radiotherapy for localized prostate cancer: Study protocol of a single arm, multicenter phase I/II trial. Radiat Oncol 2018;13:166. https://doi.org/10.1186/s13014-018-1112-0.

[18] Zilli T, Franzese C, Bottero M, Giaj-Levra N, Förster R, Zwahlen D, et al. Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiat Oncol 2019;14:98. https://doi.org/10.1186/s13014-019-0708-1.

[19] van Son MJ, Peters M, Moerland MA, Lagendijk JJW, Eppinga WSC, Shah TT, et al. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients. Int J Radiat Oncol Biol Phys 2020;107:126–35. https://doi.org/10.1016/j.ijrobp.2020.01.023.

[20] Van Son M, Peters M, Moerland M, Kerkmeijer L, Lagendijk J, Van der Voort van Zyp J. Focal salvage treatment of radiorecurrent prostate cancer: A narrative review of current strategies and future perspectives. Cancers (Basel) 2018;10:480. https://doi.org/10.3390/cancers10120480.

[21] Murgic J, Morton G, Loblaw A, D’Alimonte L, Ravi A, Wronsli M, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys 2018;102:561–7. https://doi.org/10.1016/j.ijrobp.2018.06.039.

[22] Zilli T, Scorsetti M, Zwahlen D, Franzese C, Förster R, Giaj-Levra N, et al. ONE SHOT - single shot radiotherapy for localized prostate cancer: Study protocol of a single arm, multicenter phase I/II trial. Radiat Oncol 2018;13:166. https://doi.org/10.1186/s13014-018-1112-0.

[23] Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019;394:385–95. https://doi.org/10.1016/S0140-6736(19)31131-6.

[24] Musunuru HB, Quon H, Davidson M, Cheung P, Zhang L, D’Alimonte L, et al. Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials. Radiother Oncol 2016;118:112–7. https://doi.org/10.1016/j.radonc.2015.12.020.